Organon Overview
- Year Founded
-
1923
- Status
-
Public
- Employees
-
10,000
- Stock Symbol
-
OGN
- Investments
-
12
- Share Price
-
$13.89
- (As of Friday Closing)
Organon General Information
Description
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Contact Information
Website
www.organon.comCorporate Office
- 30 Hudson Street
- Jersey City, NJ 07302
- United States
Corporate Office
- 30 Hudson Street
- Jersey City, NJ 07302
- United States
Organon Timeline
Organon Stock Performance
As of 20-Nov-2026, Organon’s stock price is $13.89. Its current market cap is $3.65B with 263M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.89 | $13.91 | $5.69 - $13.94 | $3.65B | 263M | 2.73M | $0.81 |
Organon Financials Summary
As of 30-Sep-2026, Organon has a trailing 12-month revenue of $6.1B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 11,018,749 | 10,020,077 | 11,828,480 | 11,925,845 |
| Revenue | 6,099,000 | 6,216,000 | 6,403,000 | 6,263,000 |
| EBITDA | 1,293,000 | 1,290,000 | 1,604,000 | 1,436,000 |
| Net Income | 213,000 | 187,000 | 864,000 | 1,023,000 |
| Total Assets | 13,401,000 | 12,867,000 | 13,101,000 | 12,058,000 |
| Total Debt | 8,554,000 | 8,644,000 | 8,880,000 | 8,760,000 |
Organon Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Organon Comparisons
Industry
Financing
Details
Organon Competitors (3)
One of Organon’s 3 competitors is Merck & Co., a Corporation company based in Rahway, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Pfizer | Corporation | New York, NY | ||||
| Sanofi | Corporation | Gentilly, France |
Organon Signals
Organon Investments & Acquisitions (12)
Organon’s most recent deal was a Accelerator/Incubator with Elle, MD Biotechnologies. The deal was made on 09-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Elle, MD Biotechnologies | 09-Jun-2026 | Accelerator/Incubator | Other Devices and Supplies | ||
| Myri Health | 06-May-2026 | Accelerator/Incubator | Other Healthcare Technology Systems | ||
| Merck Sharp Dohme Pharma (Oss Bio-Tech Manufacturing Facility Located in Netherlands) | 01-Jul-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Sympa Health | 01-Jan-2025 | Accelerator/Incubator | Other Healthcare Technology Systems | ||
| InBalance | 03-Nov-2024 | Accelerator/Incubator | Other Healthcare Technology Systems |
Organon ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
25.6 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Organon Exits (1)
Organon’s most recent exit was on 16-Jun-2021 from Jada System. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Jada System | 16-Jun-2021 | Completed |
|
Organon Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Dermavant Sciences | Long Beach, CA | 2016 |
Organon FAQs
-
When was Organon founded?
Organon was founded in 1923.
-
Where is Organon headquartered?
Organon is headquartered in Jersey City, NJ.
-
What is the size of Organon?
Organon has 10,000 total employees.
-
What industry is Organon in?
Organon’s primary industry is Pharmaceuticals.
-
Is Organon a private or public company?
Organon is a Public company.
-
What is Organon’s stock symbol?
The ticker symbol for Organon is OGN.
-
What is the current stock price of Organon?
As of 20-Nov-2026 the stock price of Organon is $13.89.
-
What is the current market cap of Organon?
The current market capitalization of Organon is $3.65B.
-
What is Organon’s current revenue?
The trailing twelve month revenue for Organon is $6.1B.
-
Who are Organon’s competitors?
Merck & Co., Pfizer, and Sanofi are competitors of Organon.
-
What is Organon’s annual earnings per share (EPS)?
Organon’s EPS for 12 months was $0.81.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process